GH Research (GHRS) Stock Price, News & Analysis

-0.22 (-1.95%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
45,263 shs
Average Volume
133,201 shs
Market Capitalization
$576.49 million
P/E Ratio
Dividend Yield
Price Target

GH Research MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
256.5% Upside
$39.50 Price Target
Short Interest
4.47% of Float Sold Short
Dividend Strength
News Sentiment
0.20mentions of GH Research in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.96) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

Medical Sector

760th out of 907 stocks

Pharmaceutical Preparations Industry

356th out of 421 stocks

GHRS stock logo

About GH Research Stock (NASDAQ:GHRS)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GHRS Stock Price History

GHRS Stock News Headlines

Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
GH Research PLC GHRS
See More Headlines
Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.94 per share


Free Float
Market Cap
$576.49 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Florian Schonharting M.Sc. (Econ) (Age 55)
    Co-Founder & Non-Executive Chairman of the Board
  • Dr. Theis Terwey M.D. (Age 48)
    Co-Founder & CEO
  • Mr. Magnus Halle (Age 27)
    Co-Founder & MD of Ireland
  • Ms. Julie Ryan F.C.A. (Age 38)
    Vice President of Finance
  • Mr. Aaron Cameron M.B.A. (Age 39)
    Chief Operating Officer
  • Mr. Naoise Gaffney
    VP & Head of Intellectual Property
  • Dr. Velichka Valcheva M.D. (Age 49)
    Chief Medical Officer

GHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell GH Research stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings
or view top-rated stocks.

What is GH Research's stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for GH Research's shares. Their GHRS share price targets range from $39.00 to $40.00. On average, they expect the company's stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 256.5% from the stock's current price.
View analysts price targets for GHRS
or view top-rated stocks among Wall Street analysts.

How have GHRS shares performed in 2024?

GH Research's stock was trading at $5.80 at the start of the year. Since then, GHRS shares have increased by 91.0% and is now trading at $11.08.
View the best growth stocks for 2024 here

When is GH Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GHRS earnings forecast

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.

What ETFs hold GH Research's stock?

ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL).

When did GH Research IPO?

GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GHRS) was last updated on 4/25/2024 by Staff

From Our Partners